-
Biocon Biologics Secures US Market Entry Date for Bmab 1200, a Proposed Biosimilar to Stelara®
01 Mar 2024 04:57 GMT
… fully integrated biosimilars company, Biocon Biologics is committed to expanding … Commercial Officer – Advanced Markets, Biocon Biologics Ltd, said: “This agreement … Stelara® (Ustekinumab) is a monoclonal antibody medication that prevents abnormal regulation …
-
Biocon Biologics inks licence pact with Janssen for biosimilar product
29 Feb 2024 16:46 GMT
… Drug Administration(USFDA), Biocon Biologics said in a … a subsidiary of Biocon Ltd.
Biocon Biologics and Janssen … stated.
This development enables Biocon Biologics to build further … Ustekinumab) is a monoclonal antibody medication approved for the treatment …
-
Biocon Biologics Secures US Market Entry Date for Bmab 1200, a Proposed Biosimilar to Stelara®
29 Feb 2024 15:22 GMT
… Stelara® (Ustekinumab) is a monoclonal antibody medication that prevents abnormal regulation … their respective owners.
About Biocon Biologics Limited: Biocon Biologics Ltd. (BBL), … @BioconBiologics for company updates.
Biocon Limited, publicly listed in 2004 …
-
Latest News | Biocon Biologics Inks Licence Pact with Janssen for Biosimilar Product
29 Feb 2024 15:18 GMT
… and Drug Administration(USFDA), Biocon Biologics said in a … ; Check Other Details.
Biocon Biologics and Janssen have … stated.
This development enables Biocon Biologics to build further … Ustekinumab) is a monoclonal antibody medication approved for the treatment …
-
Biocon Biologics Concludes Integration of Acquired Biosimilars Business in ~120 countries
18 Dec 2023 14:25 GMT
… portfolio of insulins and monoclonal antibodies, has successfully concluded the integration … congratulate and thank the entire Biocon Biologics team – colleagues, advisors, and … Commercial Officer - Emerging Markets. Biocon Biologics has made several key …
-
Biocon associate co Bicara Therapeutics raises over Rs 1375 crore in series C financing
14 Dec 2023 09:01 GMT
… , an associate company of Biocon Limited, has announced the … of shares by Bicara, Biocon’s shareholding in Bicara on … BCA101 and Bicara’s bifunctional antibody platform.”
In connection with … in 2023.
Read also: Biocon arm concludes integration of Viatris …
-
Biocon arm gets UK MHRA marketing authorisation for ophthalmic drug Yesafili
14 Nov 2023 06:19 GMT
… integrated global biosimilars organization. Biocon Biologics has eight commercialized … assets, including insulins, monoclonal antibodies and conjugated recombinant proteins in … oncology, immunology, and ophthalmology. Biocon Biologics has invested over USD …
-
Revolutionary Advancements Propel Biosimilar Monoclonal Antibody Market to New Heights | CAGR of 22.2%
30 Oct 2023 16:53 GMT
… -
Biogen,
Novartis AG,
Biocon,
Teva Pharmaceutical Industries Limited,
… , and commercialization of biosimilar monoclonal antibodies. Collaborations, partnerships, and investments … .com/biosimilar-monoclonal-antibody-market/purchase-options
…
-
Fierce Pharma Asia—GSK, Zhifei's vaccine pact; BioNTech's latest China deal; Biocon's biosimilar rejection
13 Oct 2023 16:52 GMT
… . Manufacturing shortfalls have derailed Biocon's FDA application … Therapeutics for an HER3-directed antibody-drug conjugate, a potential … Biotheus.
3. FDA hits Biocon's insulin copycat with …
The FDA has rejected Biocon’s biosimilar version of …
-
Biocon Biologics completes Integration of Viatris Biosimilars' Business in North America, Ahead of Schedule
06 Sep 2023 21:51 GMT
… to patients and customers, Biocon Biologics recently acquired the global … assets, including insulins and monoclonal antibodies spanning multiple therapy areas. With … (bAdalimumab), is now incorporated into Biocon Biologics' commercial organization in …